Invivyd, Inc. - Common Stock IVVD 深 沪
已收盘 10-31 16:00:00 美东时间
1.76
-0.110
-5.88%
华盛通- 最 高2.00
- 今 开1.86
- 成交量 295.43万股
- 最 低 1.75
- 昨 收 1.87
- 总市值 3.77亿
- 52周最高 2.74
- 市盈率 静 --
- 换手率 1.38%
- 52周最低 0.3546
- 委 比 61.91%
- 总股本 2.14亿
- 历史最高 78.82
- 量 比 0.66
- 振 幅 13.37%
- 历史最低 0.3546
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd, Inc. will host a live webcast on October 30, 2025, at 8:30 a.m. ET to discuss its REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention. Key executives, including Marc Elia, Tim Lee, Robert Allen, PhD, and Mark Wingertzahn, PhD, will participate. VYD2311 is designed to address the need for new prophylactic options and may offer patient-friendly administration. The webcast will provide details on...
10-28 11:01
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Cantor Fitzgerald Initiates Coverage On Invivyd with Overweight Rating, Announces Price Target of $10
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Invivyd (NASDAQ:IVVD) with a Overweight rating and announces Price Target of $10.
10-06 19:09
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd Inc. announced that the FDA has cleared the IND application for its REVOLUTION clinical program, advancing VYD2311, a monoclonal antibody candidate for COVID prevention. The DECLARATION Phase 3 trial will evaluate VYD2311's safety and efficacy vs. placebo for COVID prevention, with ~2,000 participants and options for single or monthly dosing. The LIBERTY trial will compare VYD2311's safety to mRNA vaccines and explore co-administration. B...
10-06 11:01
Invivyd Appoints New Director Amid Nasdaq Compliance
Invivyd ( ($IVVD) ) has shared an update. On September 22, 2025, Invivyd, Inc. ...
09-25 16:59
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
Invivyd, Inc. announced the appointment of Paul B. Bolno, M.D., as a Board member and Compensation Committee member. Dr. Bolno, President and CEO of Wave Life Sciences, brings extensive experience in advancing biotechnology pipelines. He will support Invivyd's efforts to develop innovative therapies for viral infectious diseases, starting with COVID-19 and potentially Long COVID. Invivyd, focused on protecting against serious viral diseases, rece...
09-24 20:01
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
Invivyd, Inc. appoints Kristie Kuhl as Chief Communications Officer to lead communications and patient advocacy efforts. Kuhl, recognized for her expertise in health communications, will help build trust and support growth as Invivyd advances its mission to develop monoclonal antibodies for viral disease prevention and treatment. She emphasizes the importance of bold, clear communication in advancing the company's mission.
09-17 11:01
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
SPEAR Study Group proposes a clinical study to evaluate monoclonal antibody VYD2311 for treating Long COVID, aiming to reduce circulating spike protein and explore clinical benefits. The study design involves maintaining high antiviral antibody levels to suppress chronic infection. Researchers Amy Proal and David Putrino will present the proposal to RECOVER-TLC. VYD2311 is expected to be a promising candidate for addressing persistent viral reser...
09-04 11:01
Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller
Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, signaling confidence in their potential for outsized returns.
08-30 00:42
